What Has Driven the Growth of the Hepatitis Therapeutics Market in Recent Years?
The hepatitis therapeutics market has seen considerable growth due to a variety of factors.
• There has been a consistent growth witnessed in the market size of hepatitis therapeutics over the past few years. In terms of market value, it is projected to escalate from $18.66 billion in 2024 to $19.27 billion in 2025, which equates to a compound annual growth rate (CAGR) of 3.2%. The factors driving this steady growth during the historic period include the development of vaccines, provisions for antiviral medicines, initiatives in public health, allocation of research funding, and introduction of novel therapies.
What Is the Forecasted Market Size and Growth Rate for The Hepatitis Therapeutics Market Size In The Coming Years?
The Hepatitis Therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a consistent evolution is anticipated for the hepatitis therapeutic market, with an expected rise to $22.75 billion in 2029, and a compound annual growth rate (CAGR) of 4.2%.
The surge in the market during the prediction span can be credited to ongoing research and development, international healthcare campaigns, changes in patient care, programs initiated by government, and increased awareness of the disease. Prominent trend projections for this period encompass advocating for patient rights and support, consistent monitoring and follow-ups, health care equality, telemedicine paired with remote care, and a concerted focus on eradicating hepatitis C.
What Factors Are Driving Growth In The Hepatitis Therapeutics Market?
The escalating rates of hepatitis infections around the world are anticipated to fuel the advancement of the hepatitis therapeutic market. Several factors such as limited access to healthcare and vaccinations, a surge in intravenous drug consumption, the prevalence of unsafe blood transfusion procedures, and substandard sanitation and hygiene conditions in certain global regions contribute to this rise in hepatitis infections. For example, as reported by the World Health Organization (WHO), a United Nations public health agency based in the US, in April 2022, a minimum of 169 acute hepatitis cases of unknown origin were recorded across 11 nations, and 350 million people globally were living with viral hepatitis B or C. However, the majority still lack access to testing and treatment. Consequently, the escalating rates of hepatitis infections are causing the hepatitis therapeutics market to expand.
What Are The Main Segments Of The Global Hepatitis Therapeutics Market?
The hepatitis therapeutics market covered in this report is segmented –
1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types
2) By Drug Class: Oral Antivirals, Immune Modulators
3) By Distribution Channel: Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers
Subsegments:
1) By Hepatitis A: Vaccines, Post-Exposure Prophylaxis (PEP)
2) By Hepatitis B: Antiviral Medications, Immune Modulators, Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs), Ribavirin, Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D, Hepatitis E, Other Viral Hepatitis Infections
Pre-Book The Hepatitis Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Hepatitis Therapeutics Market?
The prevailing trend in the hepatitis therapeutics market is the emergence of product innovations. Major players in the industry are introducing new products to maintain their market standing. For instance, in November 2022, Gilead Sciences, Inc., a biopharmaceutical firm based in the US, attained FDA approval for a drug named Vemlidy (tenofovir alafenamide) made for treating pediatric patients with chronic hepatitis B virus infection. Initially approved by the FDA in 2016, Vemlidy is a directed prodrug of tenofovir meant for daily usage in treating individuals with chronic hepatitis B virus (HBV) infection and compensated liver disease. As per the suggestions from the American Liver Foundation, it is seen as a preferred or first-line treatment for those with chronic HBV and compensated liver disease.
Who Are the Key Players In The Hepatitis Therapeutics Market?
Major companies operating in the hepatitis therapeutics market include:
• Gilead Sciences Inc.
• Bristol-Myers Squibb Co.
• AbbVie Inc.
• Merck & Co. Inc.
• Johnson & Johnson Services Inc.
• Cipla Inc.
• F Hoffmann-La Roche Ltd.
• Biocon Limited
• LAURUS Labs Ltd.
• Zydus Lifesciences Limited
• Hetero Healthcare Limited
• Novartis AG
• Sanofi SA
• GlaxoSmithKline plc
• Lupin Ltd.
• Teva Pharmaceutical Industries Ltd.
• NATCO Pharma Limited
• Pfizer Inc.
• AstraZeneca plc
• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Biocon Biopharmaceuticals Pvt. Ltd.
What Is The Most Dominant Region In The Hepatitis Therapeutics Market?
North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
